Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. Deciphera Pharmaceuticals, Inc. is not a good value stock. Deciphera Pharmaceuticals, Inc. is not very popular among insiders. Deciphera Pharmaceuticals, Inc. is a mediocre stock to choose.
Log in to see more information.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures...
DCPH Fundamental Data by TradingView

News

Brokerages Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Target Price at $24.17
Brokerages Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Target Price at $24.17

Ticker Report Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has received a consensus rating of "Hold" from the ten ratings firms that are currently covering the company, Marketbeat Ratings...\n more…

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

PR Newswire Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) Ono Announces Results of Tender Offer to...\n more…

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual

Business Wire Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer...\n more…

Swiss National Bank Lowers Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Swiss National Bank Lowers Stock Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Ticker Report Swiss National Bank lessened its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 19.1% during the 4th quarter, according to its most recent disclosure with the...\n more…

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Purchased by BNP Paribas Financial Markets
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Purchased by BNP Paribas Financial Markets

Ticker Report BNP Paribas Financial Markets boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 118.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned...\n more…

Brokerages Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) PT at $24.17
Brokerages Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) PT at $24.17

Ticker Report Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) have earned a consensus rating of "Hold" from the ten research firms that are currently covering the stock, MarketBeat...\n more…